(Q39414811)

English

The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma

scientific article published on 11 January 2012

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1 reference

based on heuristic

inferred from title

author name string

Grit Hutter

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Malte Rieken

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Alessandro Pastore

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Oliver Weigert

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Yvonne Zimmermann

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Marc Weinkauf

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Wolfgang Hiddemann

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Martin Dreyling

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

11 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Annals of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

91

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

847-856

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

The ubiquitin-proteasome proteolytic pathway

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Proteasome inhibitors in cancer therapy: lessons from the first decade

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

The development of proteasome inhibitors as anticancer drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

The proteasome: a novel target for anticancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Bortezomib: a novel chemotherapeutic agent for hematologic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentr

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Bortezomib in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Proteasome inhibition as a novel therapeutic target in human cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Update on the molecular biology of mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

The cellular origin of mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

p21Cip1 and p27Kip1 induce distinct cell cycle effects and differentiation programs in myeloid leukemia cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Control of translation initiation in animals.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

beta-TrCP-mediated ubiquitination and degradation of PHLPP1 are negatively regulated by Akt.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Caspase activation inhibits proteasome function during apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide)

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

The role of the unfolded protein response in tumour development: friend or foe?

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1377-Y

21 January 2018

Identifiers

10.1007/S00277-011-1377-Y

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39414811&oldid=1826531936"